HUP0402019A2 - CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents
CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0402019A2 HUP0402019A2 HU0402019A HUP0402019A HUP0402019A2 HU P0402019 A2 HUP0402019 A2 HU P0402019A2 HU 0402019 A HU0402019 A HU 0402019A HU P0402019 A HUP0402019 A HU P0402019A HU P0402019 A2 HUP0402019 A2 HU P0402019A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- ccr5 antagonists
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgyát szelektív CCR5 antagonistaként alkalmazhatóáltalános képletű vegyületek - ahol előnyösen R1 R4-szubsztituáltaril- vagy heteroarilcsoport; R2 alkil-, aril-, benzil- vagyciklopropil-metil-csoport; R3 adott esetben szubsztituáltheteroarilcsoport vagy piridin-N-oxidból származtatható csoport, R4 1-3 szubsztituens a hidrogén- vagy halogénatomok, alkil-, alkoxi-,halogén-alkil-, halogén-alkoxi-, alkil-szulfonil- vagy N-szubsztituáltamino-alkil-csoportok közül; R9, R1° és B hidrogénatom vagy alkil-vagy cikloalkil-csoport; és A hidrogénatom vagy alkilcsoport - éssóik, ezeket és adott esetben egy vagy több vírusellenes vagy máshatóanyagot tartalmazó, elsősorban a HIV-fertőzés okozta állapotokkezelésére szolgáló gyógyszerkészítmények és kitek képezik. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31568301P | 2001-08-29 | 2001-08-29 | |
| PCT/US2002/027389 WO2003020716A1 (en) | 2001-08-29 | 2002-08-28 | Piperidine derivatives useful as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402019A2 true HUP0402019A2 (hu) | 2005-02-28 |
| HUP0402019A3 HUP0402019A3 (en) | 2009-07-28 |
Family
ID=23225580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402019A HUP0402019A3 (en) | 2001-08-29 | 2002-08-28 | Piperidine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20040010008A1 (hu) |
| EP (1) | EP1421075B1 (hu) |
| JP (2) | JP4223950B2 (hu) |
| KR (1) | KR20040029057A (hu) |
| CN (1) | CN1304389C (hu) |
| AR (1) | AR036366A1 (hu) |
| AT (1) | ATE328879T1 (hu) |
| BR (1) | BR0212108A (hu) |
| CA (1) | CA2457861A1 (hu) |
| CY (1) | CY1105198T1 (hu) |
| DE (1) | DE60212146T2 (hu) |
| DK (1) | DK1421075T3 (hu) |
| EC (1) | ECSP044993A (hu) |
| ES (1) | ES2264491T3 (hu) |
| HK (1) | HK1061563A1 (hu) |
| HU (1) | HUP0402019A3 (hu) |
| IL (1) | IL160060A0 (hu) |
| MX (1) | MXPA04001886A (hu) |
| NO (1) | NO20041266L (hu) |
| PL (1) | PL368827A1 (hu) |
| PT (1) | PT1421075E (hu) |
| RU (1) | RU2004109510A (hu) |
| WO (1) | WO2003020716A1 (hu) |
| ZA (1) | ZA200401594B (hu) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| BR0210733A (pt) | 2001-07-02 | 2004-07-20 | Astrazeneca Ab | Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| GB0223223D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
| WO2004035541A1 (en) | 2002-10-15 | 2004-04-29 | Janssen Pharmaceutica, N.V. | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| CA2544377A1 (en) * | 2003-11-03 | 2005-05-12 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| EP1687268A1 (en) * | 2003-11-10 | 2006-08-09 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
| HU229709B1 (en) | 2004-04-13 | 2014-05-28 | Incyte Corp Wilmington | Piperazinyilpiperidine derivatives as chemokine receptor antagonists |
| WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| JP2008528477A (ja) * | 2005-01-20 | 2008-07-31 | ファイザー・リミテッド | 化合物 |
| WO2006091534A1 (en) * | 2005-02-23 | 2006-08-31 | Schering Corporation | Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| US20070010565A1 (en) * | 2005-04-25 | 2007-01-11 | Olaf Prien | New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents |
| CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| EP2205583A2 (en) | 2007-10-01 | 2010-07-14 | F. Hoffmann-Roche AG | N-heterocyclic biaryl carboxamides as ccr receptor antagonists |
| CN102066359B (zh) * | 2008-06-18 | 2013-08-21 | 弗·哈夫曼-拉罗切有限公司 | 杂芳基甲酰胺衍生物 |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| EP3083594A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten |
| AU2014364735A1 (en) | 2013-12-19 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Substituted piperidinyl-tetrahydroquinolines |
| JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| EP3083610A1 (de) * | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten |
| EP3277284B1 (en) | 2015-04-02 | 2020-08-05 | Proximagen, Llc | Novel therapies for cancer |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588722A (en) * | 1984-01-09 | 1986-05-13 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| CA2259655C (en) * | 1996-07-10 | 2003-05-13 | Schering Corporation | 1,4-di-sustituted piperidines as muscarinic antagonists |
| US5952349A (en) * | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| ES2246233T3 (es) * | 1999-05-04 | 2006-02-16 | Schering Corporation | Derivados de piperidina utiles como antagonistas de ccr5. |
| WO2001030348A1 (en) * | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
-
2002
- 2002-08-27 AR ARP020103217A patent/AR036366A1/es unknown
- 2002-08-28 JP JP2003524986A patent/JP4223950B2/ja not_active Expired - Fee Related
- 2002-08-28 CN CNB028166795A patent/CN1304389C/zh not_active Expired - Fee Related
- 2002-08-28 RU RU2004109510/04A patent/RU2004109510A/ru not_active Application Discontinuation
- 2002-08-28 WO PCT/US2002/027389 patent/WO2003020716A1/en active IP Right Grant
- 2002-08-28 CA CA002457861A patent/CA2457861A1/en not_active Abandoned
- 2002-08-28 AT AT02766142T patent/ATE328879T1/de not_active IP Right Cessation
- 2002-08-28 DE DE60212146T patent/DE60212146T2/de not_active Expired - Lifetime
- 2002-08-28 BR BR0212108-5A patent/BR0212108A/pt not_active IP Right Cessation
- 2002-08-28 HU HU0402019A patent/HUP0402019A3/hu unknown
- 2002-08-28 KR KR10-2004-7002835A patent/KR20040029057A/ko not_active Application Discontinuation
- 2002-08-28 ES ES02766142T patent/ES2264491T3/es not_active Expired - Lifetime
- 2002-08-28 MX MXPA04001886A patent/MXPA04001886A/es active IP Right Grant
- 2002-08-28 DK DK02766142T patent/DK1421075T3/da active
- 2002-08-28 EP EP02766142A patent/EP1421075B1/en not_active Expired - Lifetime
- 2002-08-28 IL IL16006002A patent/IL160060A0/xx unknown
- 2002-08-28 US US10/229,466 patent/US20040010008A1/en not_active Abandoned
- 2002-08-28 PT PT02766142T patent/PT1421075E/pt unknown
- 2002-08-28 PL PL02368827A patent/PL368827A1/xx not_active Application Discontinuation
-
2003
- 2003-07-29 US US10/629,466 patent/US7442703B2/en not_active Expired - Fee Related
- 2003-07-29 US US10/628,933 patent/US7384948B2/en not_active Expired - Fee Related
-
2004
- 2004-02-25 ZA ZA200401594A patent/ZA200401594B/en unknown
- 2004-02-27 EC EC2004004993A patent/ECSP044993A/es unknown
- 2004-03-26 NO NO20041266A patent/NO20041266L/no not_active Application Discontinuation
- 2004-06-19 HK HK04104463A patent/HK1061563A1/xx not_active IP Right Cessation
-
2006
- 2006-09-06 CY CY20061101271T patent/CY1105198T1/el unknown
-
2008
- 2008-04-17 US US12/104,914 patent/US8034933B2/en not_active Expired - Fee Related
- 2008-05-22 JP JP2008134844A patent/JP2008222722A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402019A2 (hu) | CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE264852T1 (de) | Chinolinderivate als antibakterielle mittel | |
| HUP0103460A2 (hu) | Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0401740A2 (hu) | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0202867A2 (hu) | CCR5 antagonistákként alkalmazható piperazinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0401503A2 (hu) | Indol, aza-indol és hasonló heterociklikus amido-piperazin-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
| EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
| NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
| HUP0302167A2 (hu) | Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| CY1111075T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν τα παραγωγα της 3-αμινο-αζετιδινης, τα νεα παραγωγα τους και η προετοιμασια τους | |
| NO20076006L (no) | Acetylenderivater | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| NO20054220L (no) | Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel | |
| HUP0400636A2 (hu) | Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk | |
| CY1109890T1 (el) | ΠΑΡΑΓΩΓΑ 8-ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ-6,7,8,9- ΤΕΤΡΑΫΔΡΟΠΥΡΙΜΙΔΟ[1,2-α] ΠΥΡΙΜΙΔΙΝ-4-ΟΝΗΣ | |
| HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0203528A2 (hu) | CCR5 antagonistákként alkalmazható piperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0401488A2 (hu) | Fungicid hatású 7-amino-triazolopirimidinek, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| HUP0401886A2 (hu) | Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| EA200601235A1 (ru) | Производные тиазола | |
| NO20063132L (no) | Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer | |
| NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |